Literature DB >> 7595172

The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study.

H Dralle1, G F Scheumann, C Proye, F Bacourt, A Frilling, F Limbert, G Gheri, J F Henry, M Berner, B Niederle.   

Abstract

Clinical data of 139 patients with hereditary medullary thyroid carcinoma (HMTC) from nine european centres surgically treated from 1980 to 1991 were reviewed retrospectively to analyse the value of systematic versus selective lymphadenectomy (LA). Biochemical cure rate was significantly higher in patients who underwent LA compared to patients who did not. In nodal-positive HMTC, systematic LA compared to selective LA improved biochemical cure in small but not large tumours. In nodal-negative HMTC, systematic LA compared to selective LA could not improve biochemical cure in either small or large primary tumours. To prevent local recurrences with the risk of increased surgical and tumour-related morbidity, systematic LA should be performed in all HMTC patients regardless of the primary tumour stage. However, an improvement of biochemical cure by systematic LA seems to be possible only in nodal-positive small primary tumours without distant metastases.

Entities:  

Mesh:

Year:  1995        PMID: 7595172     DOI: 10.1111/j.1365-2796.1995.tb01210.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  5 in total

1.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

2.  Single center experience in primary surgery for medullary thyroid carcinoma.

Authors:  Jörg Ukkat; Oliver Gimm; Michael Brauckhoff; Udo Bilkenroth; Henning Dralle
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

Review 3.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

4.  Skip metastases in medullary thyroid carcinoma: a single-center experience.

Authors:  Marcos R Tavares; Pedro Michaluart; Fabio Montenegro; Sergio Arap; Maria Sodre; Flavio Takeda; Lenine Brandao; Sergio Toledo; Alberto Ferraz
Journal:  Surg Today       Date:  2008-05-31       Impact factor: 2.549

5.  (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.

Authors:  Aurélien Archier; Céline Heimburger; Carole Guerin; Isabelle Morange; Fausto F Palazzo; Jean-François Henry; Olivier Schneegans; Olivier Mundler; Ahmad Esmaeel Abdullah; Frédéric Sebag; Alessio Imperiale; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.